| 19 Jun 2013 |
Just 11 Percent of Adults and 5 Percent of Children Participate in Medical Research |
Bioethics, legal and economic issues |
| 17 Jun 2013 |
BioMarker IGF Project Aims to Identify and Validate Biomarkers for the IGF-1 Signalling Pathway in Cancer |
Personalised medicine |
| 06 Jun 2013 |
European Medicines Agency recommends granting a marketing authorisation for lipegfilgrastim |
Anticancer agents & Biologic therapy |
| 05 Jun 2013 |
Bevacizumab: The First Agent to Remarkably Improve Survival in Recurrent Cervical Cancer |
Gynaecologic malignancies |
| 04 Jun 2013 |
European Medicines Agency recommends approval of pomalidomide |
Haematologic malignancies |
| 03 Jun 2013 |
FDA Approves Trametinib and Dabrafenib for Unresectable or Metastatic BRAF-Mutated Melanoma |
Melanoma |
| 14 May 2013 |
EU funded CAMINEMS project combines three emerging technologies – nanotechnology, optical technologies, and microfluidics |
Translational research |
| 11 May 2013 |
Stereotactic ablative radiotherapy is an effective alternative in patients with multiple primary lung cancers |
Lung and other thoracic tumours |
| 11 May 2013 |
Initial results from the largest prospective study of pulmonary metastasectomy in patients with colorectal cancer |
Lung and other thoracic tumours |
| 10 May 2013 |
Evaluation of performance of lung cancer screening strategy in the first three rounds of the NELSON trial |
Lung and other thoracic tumours |
| 10 May 2013 |
Different survival outcome following diagnosis of metastatic bone disease shown for EGFR mutated NSCLC patients in small retrospective study |
Lung and other thoracic tumours |
| 10 May 2013 |
First-line gefitinib effective and well tolerated in Caucasian patients with EGFR mutation-positive NSCLC |
Lung and other thoracic tumours |
| 10 May 2013 |
Enobosarm improves muscle wasting experienced by patients with NSCLC |
Lung and other thoracic tumours |
| 10 May 2013 |
Findings support the value of tumour rebiopsy in NSCLC patients |
Lung and other thoracic tumours |
| 10 May 2013 |
Study of simultaneous occurrence of EGFR mutations and HER2 gene amplifications in large series of NSCLC |
Lung and other thoracic tumours |
| 10 May 2013 |
Meta-analysis slightly favours platinum-based first-line treatment in patients with advanced/metastatic NSCLC |
Lung and other thoracic tumours |
| 30 Apr 2013 |
European Medicines Agency recommends granting a conditional marketing authorisation for vismodegib |
Anticancer agents & Biologic therapy ,
Sarcomas |
| 29 Apr 2013 |
European Medicines Agency recommends granting a marketing authorisation for enzalutamide |
Anticancer agents & Biologic therapy ,
Genitourinary cancers |
| 29 Apr 2013 |
Adequate supply level has been restored in all EU Member States and pegylated doxorubicin hydrochloride can now be used again without restrictions |
Anticancer agents & Biologic therapy ,
Breast cancer ,
Gynaecologic malignancies |
| 26 Apr 2013 |
New European system for medicines under additional monitoring |
Anticancer agents & Biologic therapy |
| 25 Apr 2013 |
Access to cancer medicines in low- and middle-income countries |
Bioethics, legal and economic issues |
| 24 Apr 2013 |
A retrospective analysis suggests that patients with NSCLC who harbour specific HER2 mutations may benefit from certain anti-HER2 treatments |
Lung and other thoracic tumours |
| 23 Apr 2013 |
New research characterises effectiveness and variability in patient recruitment and retention practices |
Bioethics, legal and economic issues |
| 22 Apr 2013 |
Cancer cachexia in the era of obesity |
Palliative and supportive care |
| 17 Apr 2013 |
Novel AKT pathway inhibitor, ARQ 092, demonstrates safety, effective target inhibition |
Anticancer agents & Biologic therapy |
